Skip to content

EPS (Diluted) at other companies

Biogen logo
BiogenBIIB
$2.15+31.1%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$1.91+2,287%
Insmed logo
InsmedINSM
-$0.76+46.5%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
-$0.73+30.5%
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
-$0.12-50.0%
uniQure logo
uniQureQURE
-$0.85-3.7%

Other financials

Income statement

See full
Revenue$2.0M-40.6%
Operating income-$57.3M-43.1%
Net income-$56.7M-44.4%

Balance sheet

See full
Cash & equivalents$297.1M+41.1%
Total debt$20.7M-12.5%
Total equity$374.1M+27.1%
Total assets$422.9M+23.0%

Cash flow

See full
Operating cash flow-$47.2M-48.3%
CapEx$165.0K+31.0%
Free cash flow-$47.4M-48.2%

Valuation

See full
Market cap$910.66M+145%
Enterprise value$634.23M+244%
P/S112.5×-10.3×

Profitability

See full
Operating margin-1,315.2%-4,060pp
Net margin-1,062.3%-251,151pp
FCF margin-1,247.7%-9,569pp

Returns & leverage

See full
Return on equity-57.4%+2.2pp
Debt / equity0.1×0.0×
Current ratio13.1×+2.2×

Where this comes from

Reported directly by Solid Biosciences Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: Solid Biosciences Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Solid Biosciences Inc.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Solid Biosciences Inc.'s EPS (diluted)?
Solid Biosciences Inc. (SLDB) reported EPS (diluted) of -$0.52 in Q1 2026.
How has Solid Biosciences Inc.'s EPS (diluted) changed year-over-year?
Solid Biosciences Inc.'s EPS (diluted) increased by 11.9% year-over-year, from -$0.59 to -$0.52.
What is the long-term trend for Solid Biosciences Inc.'s EPS (diluted)?
Over 4 years (2021 to 2025), Solid Biosciences Inc.'s EPS (diluted) has grown at a -21.1% compound annual growth rate (CAGR), from -$5.22 to -$2.02.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.